Assembly Biosciences Inc (ASMB) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital...

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by...

Assembly Biosciences Announces Effective Date of Reverse Stock Split

– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report